Aktienanalyse zu PAVmed Inc (PAVM)PAVMPAVmed Inc

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

PAVmed Inc is not a good buy right now due to its extremely low RSI of 14.111 indicating oversold conditions, and a staggering year-to-date decline of 78.51%. The current price of $1.575 is significantly below its 52-week high of $28.44, suggesting a lack of investor confidence. Furthermore, the company reported a net loss of $6.6 million for Q2 2026, down from a $12.3 million loss in the same quarter last year, but still indicating ongoing financial struggles. The main risk is its cash position of only $3.8 million, which may not be sufficient to support future operational needs, potentially leading to further financial distress.

2 analysts cover PAVM: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 17.00.